Molecular breakpoint of BCR-ABL in chronic myeloid leukemia and imatinib response

被引：0

作者：

不详

机构：

来源：

PHARMACOGENOMICS | 2010年 / 11卷 / 09期

关键词：

FUSION TRANSCRIPTS;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1202 / 1203

页数：2

共 6 条

[1] B2a2 type bcr-abl transcript chronic myelogenous leukemia (CML) patients in chronic phase (CP) on glivec achieve complete cytogenetic remission (CCyR) earlier than those with b3a2. [J].

Lomaia, Elza G. ;

Martinkevich, Irina S. ;

Ogorodnikova, Yulia S. ;

Lyschov, Anton A. ;

Bogdanov, Konstantin V. ;

Zaritskey, Andrey Yu .

BLOOD, 2006, 108 (11) :278B-278B

[2] Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript [J].

Lucas, Claire M. ;

Harris, Robert J. ;

Giannoudis, Athina ;

Davies, Andrea ;

Knight, Katy ;

Watmough, Sarah J. ;

Wang, Lihui ;

Clark, Richard E. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (10) :1362-1367

[3] Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts [J].

Polampalli, S. ;

Choughule, A. ;

Negi, N. ;

Shinde, S. ;

Baisane, C. ;

Amre, P. ;

Subramanian, P. G. ;

Gujral, S. ;

Prabhash, K. ;

Parikh, P. .

GENETICS AND MOLECULAR RESEARCH, 2008, 7 (04) :1138-1149

[4]

de Lemos JAR, 2005, GENET MOL RES, V4, P803

[5] Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts [J].

Sharma, Pratibha ;

Kumar, Lalit ;

Mohanty, Sujata ;

Kochupillai, Vinod .

ANNALS OF HEMATOLOGY, 2010, 89 (03) :241-247

[6]

Vega-Ruiz A, 2007, BLOOD, V110, p576A

← 1 →